Thomas MSc - CirChem AB Chief Officer
| CIRCHE Stock | SEK 2.84 0.10 3.40% |
Insider
Thomas MSc is Chief Officer of CirChem AB
| Age | 71 |
| Phone | 46 7 08 61 17 80 |
| Web | https://circhem.com |
CirChem AB Management Efficiency
The company has return on total asset (ROA) of (0.2435) % which means that it has lost $0.2435 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8823) %, meaning that it generated substantial loss on money invested by shareholders. CirChem AB's management efficiency ratios could be used to measure how well CirChem AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andrew Strain | AAC Clyde Space | 42 | |
| Marie MSc | Clinical Laserthermia Systems | 44 | |
| Kulwinder Bhumbra | AAC Clyde Space | N/A | |
| Mats Thideman | AAC Clyde Space | 60 | |
| Stefan Stralsjo | AAC Clyde Space | 51 | |
| Anders Sandberg | Alzinova AB | 51 | |
| Mats Ekelund | Clinical Laserthermia Systems | N/A | |
| Kristina Torfgard | Alzinova AB | N/A | |
| Karin Peterson | Clinical Laserthermia Systems | N/A | |
| LarsErik Eriksson | Clinical Laserthermia Systems | 74 | |
| Mattias rth | AAC Clyde Space | 42 | |
| Rolf Bornschein | Clinical Laserthermia Systems | N/A | |
| Hakan Skogstrom | Alzinova AB | 62 | |
| Stefania Mandirola | AAC Clyde Space | N/A | |
| Dino Lorenzini | AAC Clyde Space | N/A | |
| Peter Anderson | AAC Clyde Space | N/A | |
| Anders Bylock | Alzinova AB | N/A | |
| Luis Gomes | AAC Clyde Space | 52 | |
| Andrew Waller | Intervacc AB | N/A | |
| Dan Mogren | Clinical Laserthermia Systems | N/A | |
| Patrik Hellberg | Intervacc AB | N/A | |
Management Performance
| Return On Equity | -0.88 | |||
| Return On Asset | -0.24 |
CirChem AB Leadership Team
Elected by the shareholders, the CirChem AB's board of directors comprises two types of representatives: CirChem AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CirChem. The board's role is to monitor CirChem AB's management team and ensure that shareholders' interests are well served. CirChem AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CirChem AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Magnus Gink, Head Devel | ||
| Andreas Wadstedt, Chief Officer | ||
| Petra Sas, Interim Officer | ||
| Thomas MSc, Chief Officer | ||
| William Soraa, Sales Mang |
CirChem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CirChem AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.88 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (4.97) % | |||
| Current Valuation | 56.2 M | |||
| Shares Outstanding | 17.19 M | |||
| Shares Owned By Insiders | 18.66 % | |||
| Shares Owned By Institutions | 13.24 % | |||
| Price To Book | 1.08 X | |||
| Price To Sales | 20.74 X | |||
| Revenue | 85.55 K |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in CirChem Stock
CirChem AB financial ratios help investors to determine whether CirChem Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CirChem with respect to the benefits of owning CirChem AB security.